(Health-NewsWire.Net, October 10, 2015 ) Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.81% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=399076
Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 1015 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.
The different segments of patients with MM are based on their eligibility for an SCT
What combination therapies are used for various segments?
What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?
There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.
What are the dominant mechanisms of action across marketed products?
Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
Which product is used more in each country?
Will there be any label expansions of existing market leaders in any of the countries?
Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.
What are the various epidemiology trends in each country?
What factors contribute to the overall epidemiology?
The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.
What are the various pipeline products based on molecule type, mechanism of action and stage of development?
Which class is most prominent within the pipeline?
Do the pipeline molecules offer an advantage over commercially proven mechanisms?
What are the late-pipeline products expected to be launched in each country in the near future?
Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.
How do failure rates vary by product stage of development, molecule type, and mechanism of action?
How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
What are the current promising pipeline drugs and their efficacy data?
Over the 20142020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.
Which markets make the most significant contribution to the current market size?
What are the incidence, diagnosis and treatment trends in these markets?
What are the factors responsible for difference in the treatment patterns within the four markets?
Which factors will influence growth rates?
Will new market entrants lead to substantial changes in annual therapy costs?
Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.
Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Will the patent expiration be offset by the approval of new therapies?
Browse Detail Report With TOC @ http://www.researchmoz.us/myeloma-therapeutics-in-asiapacific-markets-to-2021-growth-driven-by-rising-prevalence-continued-success-of-velcade-revlimid-and-emerging-supplementary-treatments-report.html
Reasons To Buy
This report will enable you to:
Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.
Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.
Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Etiology 10
2.3 Pathophysiology 11
2.4 Symptoms 12
2.5 Diagnosis and Classification 12
2.6 Epidemiology 15
2.7 Prognosis and Disease Staging 16
2.8 Treatment Options 18
2.8.1 Treatment Algorithm 20
2.8.2 Initial Therapy for Newly Diagnosed Symptomatic Disease 20
2.8.3 Maintenance Therapy 25
2.8.4 Therapy for Relapsed or Refractory Myeloma 26
3 Marketed Products 32
3.1 Overview 32
3.2 Immunomodulatory Agents 32
3.2.1 Thalomid (thalidomide) Celgene 32
3.2.2 Revlimid (lenalidomide) Celgene 33
3.2.3 Pomalyst (pomalidomide) Celgene 33
3.3 Proteasome Inhibitors 34
3.3.1 Velcade (bortezomib) Millennium Pharmaceuticals/Takeda 34
3.3.2 Kyprolis (carfilzomib) Onyx 34
3.4 Histone Deacetylase Inhibitors 35
3.4.1 Farydak (panobinostat) Novartis 35
3.5 Chemotherapy 36
3.5.1 Doxil (doxorubicin HCl liposome injection) Janssen 36
3.6 Comparative Efficacy and Safety of Marketed Products 36
4 Pipeline Products 40
4.1 Overall Pipeline 40
4.2 Pipeline Analysis by Molecular Target 41
5 Clinical Trials 45
5.1 Failure Rate 45
5.2 Patient Enrolment and Clinical Trial Size 47
5.3 Duration 53
5.4 Competitive Clinical Trials Metrics Analysis 57
5.5 Promising Drug Candidates in the Pipeline 58
5.5.1 Daratumumab Johnson & Johnson 58
5.5.2 Elotuzumab AbbVie and Bristol Myers Squibb 59
5.5.3 Ixazomib Millennium Pharmaceuticals 60
5.5.4 Zolinza (vorinostat) Merck 62
5.5.5 ARRY-520 (filanesib) Array Biopharma 63
5.5.6 Aplidin (plitidepsin) PharmaMar 64
5.6 Heat Map for Pipeline Products 65
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=399076
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Mr. Nachiket Ghumare,
USA-Canada Toll Free: 866-997-4948
Researchmoz Global Pvt.Ltd